相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
G. D. Marijn Veerman et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
Zhangfeng Huang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS
Xiangjun Qiu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability
Ali S. Abdelhameed et al.
PLOS ONE (2019)
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Yuichiro Ohe et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
Karen L. Reckamp et al.
CANCER (2014)
A Phase I Open-Label Study to Investigate the Potential Drug-Drug Interaction Between Single-Dose Dacomitinib and Steady- State Paroxetine in Healthy Volunteers
Ana Ruiz-Garcia et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
Carlo L. Bello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1,-2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
Toshiaki Takahashi et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2011)
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Kim-Son H. Nguyen et al.
CLINICAL LUNG CANCER (2009)
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
Falm Eskens et al.
BRITISH JOURNAL OF CANCER (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
分享论文
